[Hib vaccine].

Abstract

Haemophilus influenzae type b (Hib) is the most common cause of bacterial meningitis among children. Hib conjugate vaccines, capsule polysaccharide (polyribosylribitol phosphate: PRP) conjugated with carrier protein, are very effective and safe. Hib vaccine conjugated with tetanus toxoid (PRP-T: ActHIB) was licensed in 1992 in France. After introduction of Hib vaccines among young infants routinely, the incidence of Hib meningitis dramatically decreased in many countries. In Japan, according to two prospective studies for bacterial meningitis in 1996-98, 8.6-8.9 cases of Hib meningitis were reported among 100 thousand children under 5 years of age every year. ActHIB was licensed in January of 2007 in Japan, and will be on the market in October, 2008. We hope that Hib meningitis will be eliminated by the routine shots of ActHIB under immunization low in near future.

• Authors: Chiaki Miyazaki
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 66 Issue 10 Pg. 1985-9 (Oct 2008) ISSN: 0047-1852 [Print] Japan
• PMID: 18939501 (Publication Type: English Abstract, Journal Article)

Chemical References

• Carrier Proteins
• Haemophilus Vaccines
• Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate
• Polysaccharides
• Tetanus Toxoid
• Vaccines, Conjugate
• polyribitol phosphate

Topics

• Carrier Proteins
• Child
• Child, Preschool
• Drug Design
• Haemophilus Vaccines
• Haemophilus influenzae type b (immunology)
• Humans
• Immunization Programs (trends)
• Immunization Schedule
• Japan
• Meningitis, Bacterial (microbiology, prevention & control)
• Polysaccharides
• Tetanus Toxoid
• Vaccines, Conjugate